Message from our CEO
With our historical success with HORIZANT® (gabapentin enacarbil) Extended-Release Tablets since XenoPort’s launch in June 2013, we’re more motivated than ever to expand our educational efforts and increase access to HORIZANT. In doing so, we believe we’ll be able to meaningfully benefit more patients and create value for our shareholders.
As an organization, we have our list of priorities and it begins with People. Whether it’s our employees that bring skills and expertise critical to our success, our investors that trust us to build a strong company or our vendors that provide cutting-edge products and services, we believe that People make all the difference. It’s People that will continue to help us make a positive impact in patients’ lives.
People will drive our continued performance as a company. Here at XenoPort we are focused on a few key performance measures to maximize our success. They include:
- Growing HORIZANT sales by:
- Enabling our highly-trained NeuroScience Health Specialists to service Health Care Providers, allowing them to make the best decisions about treatment options for patients;
- Ensuring that patients obtain the best information about their treatment options;
- Managing our expenses to align with our commercial focus; and
- Seeking opportunities to expand our revenue growth.
We believe that our relentless focus on these three metrics will be the key to driving value to our stakeholders moving forward and will result in an even stronger organization.
We are enthusiastic about HORIZANT and energized by the opportunities that lie ahead for XenoPort.
We encourage you to learn more about XenoPort by exploring our website and reviewing our Annual Report. As always, thank you for your support.
Forward-Looking Statement of XenoPort, Inc., Santa Clara, CA, USA
This above message from XenoPort’s CEO contains “forward-looking” statements, including, without limitation, all statements related to the potential for XenoPort to create value for its stockholders and XenoPort’s future performance, including growing HORIZANT sales, increasing access to HORIZANT and potential future opportunities to expand revenue growth. Words such as “believe,” “opportunities,” “potential,” “seeking,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort’s current expectations. Forward-looking statements involve risks and uncertainties. XenoPort’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to XenoPort’s relative lack of commercialization experience and its ability to successfully market and sell HORIZANT, including XenoPort’s ability to maintain a sales force comprising of both XenoPort-employed sales representatives and contract sales representatives, and XenoPort’s reliance on its contract sales organization to maintain sales, marketing, distribution, supply chain and other sufficient capabilities to sell HORIZANT; XenoPort’s dependence on the success of its strategies for HORIZANT commercialization, promotion and distribution, as well as its ability to successfully execute on these activities and to comply with applicable laws, regulations and regulatory requirements; the competitive environment for and the degree of market acceptance of HORIZANT; obtaining appropriate pricing and reimbursement for HORIZANT in an increasingly challenging environment; that XenoPort may be unable to, or may otherwise be unsuccessful in, expanding either the commercial opportunity for HORIZANT or revenue growth; the availability of resources to support XenoPort’s operations; XenoPort’s substantial outstanding debt and debt service obligations, which could, among other things, limit its flexibility in planning for, or reacting to, changes in its business and its industry; as well as risks related to future opportunities and plans, including the uncertainty of future revenue growth. These and other risk factors are discussed under the heading “Risk Factors” in XenoPort’s most recent Annual Report on Form 10-K and in its most Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), as well as any amendments thereto reflected in subsequent filings with the SEC. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in XenoPort’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.